Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: Implication of steroid hormone receptors (MR/GR)

Hormone Molecular Biology and Clinical Investigation

Volumn 19, Issue 2, 2014, Pages 89-101

  Even, Sarah Elisabeth Louise ^a   Dulak Lis, Maria Gabriela ^a   Touyz, Rhian M ^a   Dinh Cat, Aurelie Nguyen ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cardiometabolic syndrome; corticosteroid receptors; perivascular adipocytes; vascular function

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADIPOCYTOKINE; ADIPONECTIN; ALDOSTERONE; ALDOSTERONE RECEPTOR; ANGIOTENSIN II; APELIN; CHEMERIN; COPPER ZINC SUPEROXIDE DISMUTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C BETA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID ANTAGONIST; REACTIVE OXYGEN METABOLITE;

ADIPOSE TISSUE; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; BODY FAT DISTRIBUTION; CARDIOMETABOLIC SYNDROME; CARDIOVASCULAR DISEASE; CORTICOSTEROID METABOLISM; CUSHING SYNDROME; ENDOTHELIAL DYSFUNCTION; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIVASCULAR ADIPOSE TISSUE; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; INFLAMMATION; METABOLIC SYNDROME X; METABOLISM;

ADIPOSE TISSUE; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID;

EID: 84928649148     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2014-0013     Document Type: Review

References (150)

1. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105-20.
2. Erratum in: N Engl J Med 2010;362:2433.
3. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378: 804-14.
4. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
5. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005;64:163-9.
6. Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006;27:449-67.
7. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
8. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 2007;75:690-701.
9. Eringa EC, Bakker W, Smulders YM, Serné EH, Yudkin JS, Stehou-wer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcircu-lation 2007;14:389-402.
10. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerbäck S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-25.
11. Erratum in: N Engl J Med 2009;361:1123.
12. Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes 2011;2011:490650.
13. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med 2013;19:1252-63.
14. Giralt M, Villarroya F. White, brown, beige/brite: different adipose cells for different functions? Endocrinology 2013;154:2992-3000.
15. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999;7:355-62.
16. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001;37:845-50.
17. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356-62.
18. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in hYpertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endo-crinol Metab 2008;93:2566-71.
19. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008;19:88-90.
20. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010;12:252-7.
21. Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007;13:2180-4.
22. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009;104:541-9.
23. Rajsheker S, Manka D, Blomkalns AL, Chatterjee TK, Stoll LL, Weintraub NL. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 2010;10:191-6.
24. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertension 1991;13:277-96.
25. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 2002;16:1057-63.
26. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, Gollasch M. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004;44: 271-6.
27. Dubrovska G, Verlohren S, Luft FC, Gollasch M. Mechanisms of ADRF release from rat aortic adventitial adipose tissue. Am J Physiol 2004;286:H1107-13.
28. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007;151:323-31.
29. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009;119:1661-70.
30. Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007;117:387-96.
31. Ma L, Ma S, He H, Yang D, Chen X, Luo Z, Liu D, Zhu Z. Perivascu-lar fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res 2010;33:446-53.
32. Fernández-Alfonso MS, Gil-Ortega M, García-Prieto CF, Aranguez I, Ruiz-Gayo M, Somoza B. Mechanisms of perivas-cular adipose tissue dysfunction in obesity. Int J Endocrinol 2013;2013:402053.
33. Gil-Ortega M, Condezo-Hoyos L, García-Prieto CF, Arribas SM, González MC, Aranguez I, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Imbalance between pro and anti-oxidant mechanisms in perivascular adipose tissue aggravates long-term high-fat diet-derived endothelial dysfunction. PLoS One 2014;9:e95312.
34. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signaling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817-20.
35. Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med 2011;9:25.
36. Szasz T, Bomfim GF, Webb RC. The influence of perivascular adipose tissue on vascular homeostasis. Vasc Health Risk Manag 2013;9:105-16.
37. Schleifenbaum J, Köhn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, Crean CS, Luft FC, Huang Y, Schubert R, Gollasch M. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens 2010;28:1875-82.
38. Xi W, Satoh H, Kase H, Suzuki K, Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxa-tion in response to globular adiponectin. Biochem Biophys Res Commun 2005;332:200-5.
39. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, Gollasch M. Adiponectin is a novel humoral vasodilator. Cardio-vasc Res 2007;75:719-27.
40. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008;114:361-74.
41. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010;393:668-72.
42. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011;19:1552-9.
43. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006;12:RA112-9.
44. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothe-lium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun 2009;383:503-8.
45. Vallejo S, Romacho T, Angulo J, Villalobos LA, Cercas E, Leivas A, Bermejo E, Carraro R, Sánchez-Ferrer CF, Peiró C. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyl-transferase activity. PLoS One 2011;6:e27299.
46. Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010;15:225-9.
47. Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. Circ J 2010;74:1479-87.
48. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 2006;71:363-73.
49. Knock GA, Snetkov VA, Shaifta Y, Connolly M, Drndarski S, Noah A, Pourmahram GE, Becker S, Aaronson PI, Ward JP. Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca2+ sensitization. Free Radic Biol Med 2009;46:633-42.
50. Gao YJ, Hirota S, Zhang DW, Janssen LJ, Lee RM. Mechanisms of hydrogen-peroxide-induced biphasic response in rat mesenteric artery. Br J Pharmacol 2003;138:1085-92.
51. Gil-Longo J, González-Vázquez C. Characterization of four different effects elicited by H2O2 in rat aorta. Vascul Pharmacol 2005;43:128-38.
52. Marvar PJ, Hammer LW, Boegehold MA. Hydrogen peroxide-dependent arteriolar dilation in contracting muscle of rats fed normal and high salt diets. Microcirculation 2007;14:779-91.
53. Rahmouni K, Haynes WG. Endothelial effects of leptin: implications in health and diseases. Curr Diab Rep 2005;5:260-6.
54. Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, Sherwood RA, Kearney MT. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J 2006;27:2294-9.
55. Mohammed MM, Myers DS, Sofola OA, Hainsworth R, Drinkhill MJ. Vasodilator effects of leptin on canine isolated mesenteric arteries and veins. Clin Exp Pharmacol Physiol 2007;34:771-4.
56. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 2011;58:271-9.
57. Beltowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol 2012;39:168-78.
58. Zhang DX, Yi FX, Zou AP, Li PL. Role of ceramide in TNF-a-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am J Physiol Heart Circ Physiol 2002;283:H1785-94.
59. Wort SJ, Ito M, Chou PC, Mc Master SK, Badiger R, Jazrawi E, de Souza P, Evans TW, Mitchell JA, Pinhu L, Ito K, Adcock IM. Synergistic induction of endothelin-1 by tumor necrosis factor a and interferon y is due to enhanced NF-KB binding and histone acety-lation at specific KB sites. J Biol Chem 2009;284:24297-305.
60. Ohkawa F, Ikeda U, Kawasaki K, Kusano E, Igarashi M, Shimada K. Inhibitory effect of interleukin-6 on vascular smooth muscle contraction. Am J Physiol 1994;266:H898-902.
61. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II-induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007;27:2576-81.
62. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [125I]-(Pyr1) Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132:1255-60.
63. Kagiyama S, Fukuhara M, Matsumura K, Lin YZ, Fuji K, Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 2005;125:55-9.
64. Salcedo A, Garijo J, Monge L, Fernández N, García-Villalón AL, Sánchez Turrión V, Cuervas-Mons V, Diéguez G. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept 2007;144:50-5.
65. Japp AG, Newby DE. The apelin-APJ system in heart failure. pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008;75:1882-92.
66. Ceylan-Isik AF, Kandadi MR, Xu X, Hua Y, Chicco AJ, Ren J, Nair S. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 2013;63:4-13.
67. Zhang CH, Hein TW, Wang W, Kuo L. Divergent roles of angioten-sin II AT1 and AT2 receptors in modulating coronary microvascu-lar function. Circ Res 2003;92:322-9.
68. Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol 2010;634:107-12.
69. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
70. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Ante-nucci G, Maffei A, Cifelli G, Iorio L, Landolfi A, Frati G, Lembo G. Resistin impairs insulin-evoked vasodilation. Diabetes 2008;57:577-83.
71. Lobato NS, Neves KB, Filgueira FP, Fortes ZB, Carvalho MH, Webb RC, Oliveira AM, Tostes RC. The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK-ERK1/2 pathway. Life Sci 2012;91:600-6.
72. Watts SW, Dorrance AM, Penfold ME, Rourke JL, Sinal CJ, Seitz B, Sullivan TJ, Charvat TT, Thompson JM, Burnett R, Fink GD. Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol 2013;33:1320-8.
73. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011;34:307-10.
74. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signaling in rat aorta: a link to vascular dysfunction in obesity? Clin Sci (Lond) 2014;127:111-22.
75. Payne GA, Borbouse L, Bratz IN, Roell WC, Bohlen HG, Dick GM, Tune JD. Endogenous adipose-derived factors diminish coronary endothelial function via inhibition of nitric oxide synthase. Microcirculation 2008;15:417-26.
76. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shi-momura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61.
77. Aroor AR, Mandavia C, Ren J, Sowers JR, Pulakat L. Mitochondria and oxidative stress in the cardiorenal metabolic syndrome. Cardiorenal Med 2012;2:87-109.
78. Whaley-Connell A, Sowers JR. Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep 2012;14:360-5.
79. Kobayasi R, Akamine EH, Davel AP, Rodrigues MA, Carvalho CR, Rossoni LV. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens 2010;28:2111-9.
80. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y. Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 2012;110:1211-6.
81. Schäfer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Lüscher TF, Verrey F, Matter CM. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J 2013;34:3515-24.
82. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009;16:94-112.
83. Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci 2013;14:21525-50.
84. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011;15:1911-26.
85. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:447-57.
86. McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses 2010;75:276-81.
87. Inoguchi T, Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005;6:495-501.
88. Payne GA, Bohlen HG, Dincer UD, Borbouse L, Tune JD. Periad-ventitial adipose tissue impairs coronary endothelial function via PKC-beta-dependent phosphorylation of nitric oxide syn-thase. Am J Physiol Heart Circ Physiol 2009;297:H460-5.
89. Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 2013;10:472-82.
90. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
91. Thengchaisri N, Kuo L. Hydrogen peroxide induces endothelium dependent and-independent coronary arteriolar dilation: role of cyclooxygenase and potassium channels. Am J Physiol Heart Circ Physiol 2003;285:H2255-63.
92. Lucchesi PA, Belmadani S, Matrougui K. Hydrogen peroxide acts as both vasodilator and vasoconstrictor in the control of perfused mouse mesenteric resistance arteries. J Hypertens 2005;23:571-9.
93. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 2006;231:237-51.
94. Moreno JM, Rodriguez Gomez I, Wangensteen R, Perez-Abud R, Duarte J, Osuna A, Vargas F. Mechanisms of hydrogen peroxide-induced vasoconstriction in the isolated perfused rat kidney. J Physiol Pharmacol 2010;61:325-32.
95. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 2009;302:111-7.
96. Zennaro MC, Caprio M, Fève B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 2009;20:444-51.
97. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010;52:401-9.
98. Stiefel P, Vallejo-Vaz AJ, García Morillo S, Villar J. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011;2011:685238.
99. Ronconi V, Turchi F, Appolloni G, di Tizio V, Boscaro M, Giac-chetti G. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr Vasc Pharmacol 2012;10:238-46.
100. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 2013;50:89-99.
101. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998;24:789-96.
102. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007;30:2349-54.
103. Lastra-Gonzalez G, Manrique-Acevedo C, Sowers JR. New trends in insulin resistance: the role of mineralocorticoids. J Cardiometab Syndr 2007;2:233-4.
104. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Man-rique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293:H2009-23.
105. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, Caprio M. Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol 2013;137:99-106.
106. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009;308:53-62.
107. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-75.
108. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticos-teroid-induced adipogenesis. FASEB J 2007;21:2185-94.
109. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, Touyz RM. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 2011;58:479-88.
110. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-depend-ent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069-78.
111. Corbould A. Efects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res 2007;39:915-8.
112. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proin-flammatory adipokines. Circulation 2008;117:2253-61.
113. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84:164-72.
114. Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Segal MS, Christou DD. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond) 2013;125:513-20.
115. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457-63.
116. Matsumoto S, Takebayashi K, Aso Y. The efect of spironol-actone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006;55:1645-52.
117. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006;91:2214-7.
118. Kraus D, Jäger J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005;37:455-9.
119. Torpy DJ, Bornstein SR, Taylor W, Tauchnitz R, Gordon RD. Leptin levels are suppressed in primary aldosteronism. Horm Metab Res 1999;31:533-6.
120. Haluzík M, Sindelka G, Widimský J Jr, Prázný M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyper-aldosteronism before and afer treatment: relationships to insulin sensitivity. J Hum Hypertens 2002;16:41-5.
121. Kamari Y, Shimoni N, Koren F, Peleg E, Sharabi Y, Grossman E. High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the renin-angiotensin-aldosterone system. J Hypertens 2010;28:95-101.
122. Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolfen-buttel BH, Navis G. Low dietary sodium and exogenous angio-tensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007;92:1821-6.
123. Flynn C, Bakris GL. Interaction between adiponectin and aldos-terone. Cardiorenal Med 2011;1:96-101.
124. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Taka-hashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-81.
125. Cao Y, Tao L, Yuan YX, Jiao XY, Lau WB, Wang YJ, Christopher T, Lopez B, Chan L, Goldstein B, Ma XL. Endothelial dysfunction in adiponectin defciency and its mechanisms involved. J Mol Cell Cardiol 2009;46:413-9.
126. Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A, Wolfson N. Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis? Int J Obes (Lond) 2009;33:553-8.
127. Li FY, Cheng KK, Lam KS, Vanhoutte PM, Xu A. Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol (Oxf) 2011;203:167-80.
128. Li P, Zhang XN, Pan CM, Sun F, Zhu DL, Song HD, Chen MD. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 2011;43:464-9.
129. Jiang H, Ye XP, Yang ZY, Zhan M, Wang HN, Cao HM, Xie HJ, Pan CM, Song HD, Zhao SX. Aldosterone directly afects apelin expression and secretion in adipocytes. J Mol Endocrinol 2013;51:37-48.
130. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-7.
131. Park YM, Lim BH, Touyz RM, Park JB. Expression of NAD(P)H oxi-dase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. J Korean Med Sci 2008;23:1039-45.
132. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776-83.
133. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
134. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
135. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001;286:327-34.
136. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-505.
137. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9.
138. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004;59:359-93.
139. Kumari M, Chandola T, Brunner E, Kivimaki M. A nonlinear relationship of generalized and central obesity with diurnal cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab 2010;95:4415-23.
140. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-3.
141. Chanson P, Salenave S. Metabolic syndrome in Cushing's syndrome. Neuroendocrinology 2010;92(Suppl 1):96-101.
142. Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta 2014;1842:473-81.
143. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70.
144. Masuzaki H, Flier JS. Tissue-specifc glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)-a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:255-62.
145. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-defcient mice. Diabetes 2004;53:931-8.
146. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specifc glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005;54:1023-31.
147. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J. The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 2010;204:153-64.
148. Gu P, Xu A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Rev Endocr Metab Disord 2013;14:49-58.
149. Mérial-Kieny C, Lonchampt M, Cogé F, Verwaerde P, Galizzi JP, Boutin JA, Lafontan M, Levens N, Galitzky J, Félétou M. Endothelin-1 inhibits TNF alpha-induced iNOS expression in 3T3-F442A adipocytes. Br J Pharmacol 2003;139:935-44.
150. Koh EH, Kim M, Ranjan KC, Kim HS, Park HS, Oh KS, Park IS, Lee WJ, Kim MS, Park JY, Youn JH, Lee KU. eNOS plays a major role in adiponectin synthesis in adipocytes. Am J Physiol Endo-crinol Metab 2010;298:E846-53.